Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNASDAQ:MOLNNASDAQ:RZLTNASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$8.00-2.8%$7.37$5.51▼$11.73$156.26MN/A44,844 shs51,957 shsMOLNMolecular Partners$3.97+11.2%$4.32$3.32▼$12.70$160.29M1.1619,357 shs6,378 shsRZLTRezolute$2.75+4.2%$3.47$2.22▼$6.19$166.47M0.97506,472 shs907,137 shsSPROSpero Therapeutics$0.75+1.9%$0.75$0.51▼$1.72$42.16M0.64189,867 shs35,943 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics0.00%+4.44%+8.84%-7.19%+799,999,900.00%MOLNMolecular Partners0.00%+2.58%-4.80%-25.86%+1.53%RZLTRezolute0.00%+11.34%-17.42%-43.53%-15.12%SPROSpero Therapeutics0.00%+25.70%-1.41%-17.12%-49.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMOLNMolecular Partners1.6145 of 5 stars3.83.00.00.00.00.00.6RZLTRezolute2.8878 of 5 stars3.63.00.00.02.54.20.0SPROSpero Therapeutics4.1037 of 5 stars3.33.00.04.70.60.82.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.00150.00% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00202.27% UpsideRZLTRezolute 3.14Buy$26.43861.04% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00562.95% UpsideCurrent Analyst Ratings BreakdownLatest SPRO, ACTU, MOLN, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/13/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/13/2025RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $9.002/10/2025RZLTRezoluteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/5/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/4/2025RZLTRezoluteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/30/2025SPROSpero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 4/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AMOLNMolecular Partners$4.97M32.25N/AN/A$5.41 per share0.73RZLTRezoluteN/AN/AN/AN/A$1.65 per shareN/ASPROSpero Therapeutics$27.40M1.54$0.47 per share1.62$2.02 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/AMOLNMolecular Partners-$69.04M-$1.81N/AN/AN/A-1,043.01%-39.31%-35.46%5/15/2025 (Estimated)RZLTRezolute-$68.46M-$1.22N/AN/AN/AN/A-70.27%-62.41%5/13/2025 (Estimated)SPROSpero Therapeutics$22.81M-$1.2710.78N/AN/A3.30%4.03%2.21%5/13/2025 (Estimated)Latest SPRO, ACTU, MOLN, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024SPROSpero Therapeutics-$0.35-$0.38-$0.03-$0.38$12.40 million$15.04 million3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/A2/12/2025Q2 2025RZLTRezolute-$0.33-$0.22+$0.11-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.067.96%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68MOLNMolecular PartnersN/A14.3314.33RZLTRezoluteN/A9.309.30SPROSpero TherapeuticsN/A2.682.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AMOLNMolecular Partners26.55%RZLTRezolute82.97%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipACTUActuate TherapeuticsN/AMOLNMolecular Partners5.93%RZLTRezolute18.39%SPROSpero Therapeutics4.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.53 millionN/AN/AMOLNMolecular Partners18040.38 million37.97 millionNot OptionableRZLTRezolute4060.54 million49.40 millionOptionableSPROSpero Therapeutics15055.90 million52.05 millionOptionableSPRO, ACTU, MOLN, and RZLT HeadlinesRecent News About These CompaniesSpero Therapeutics Analyst RatingsApril 7, 2025 | benzinga.comTD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)April 2, 2025 | markets.businessinsider.comWe're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn RateMarch 29, 2025 | finance.yahoo.comSpero Therapeutics reports Q4 EPS (38c), consensus (31c)March 28, 2025 | markets.businessinsider.comSpero halts development on another antibiotic in latest reprioritizationMarch 28, 2025 | fiercebiotech.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 28, 2025 | finanznachrichten.deSpero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comSpero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue EstimatesMarch 27, 2025 | zacks.comSpero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateMarch 27, 2025 | globenewswire.com1SPRO : A Glimpse of Spero Therapeutics's Earnings PotentialMarch 26, 2025 | benzinga.comSpero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025March 18, 2025 | globenewswire.comUPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comSpero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comSpero Therapeutics CEO sells shares worth $121,159February 6, 2025 | msn.comSpero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu Sells 20,689 SharesFebruary 6, 2025 | insidertrades.comSpero therapeutics CFO sells $16,137 in stockFebruary 6, 2025 | msn.comSpero Therapeutics COO Timothy Keutzer sells shares for $44,097February 6, 2025 | msn.comOptimistic Buy Rating for Spero Therapeutics Amid Strategic Initiatives and PartnershipsJanuary 30, 2025 | markets.businessinsider.comSpero Therapeutics Inc SPROJanuary 16, 2025 | morningstar.comSpero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should KnowJanuary 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Archer Aviation Stock Could Soar After Palantir PartnershipBy Jeffrey Neal Johnson | March 20, 2025View Why Archer Aviation Stock Could Soar After Palantir PartnershipIntel-Taiwan Semiconductor Alliance Fuels Turnaround HopesBy Jeffrey Neal Johnson | April 8, 2025View Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes4 Undervalued Growth Stocks to Buy and Hold for the Long TermBy Sarah Horvath | March 21, 2025View 4 Undervalued Growth Stocks to Buy and Hold for the Long TermTaiwan Semiconductor Attracts Big Money on NVIDIA Chip GrowthBy Gabriel Osorio-Mazilli | March 24, 2025View Taiwan Semiconductor Attracts Big Money on NVIDIA Chip GrowthBoeing Breaks Out: What the Market Is Signaling NowBy Gabriel Osorio-Mazilli | March 25, 2025View Boeing Breaks Out: What the Market Is Signaling NowSPRO, ACTU, MOLN, and RZLT Company DescriptionsActuate Therapeutics NASDAQ:ACTU$8.00 -0.24 (-2.86%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Molecular Partners NASDAQ:MOLN$3.89 +0.32 (+8.94%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Rezolute NASDAQ:RZLT$2.75 +0.11 (+4.17%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.71 -0.04 (-1.45%) As of 04/17/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Spero Therapeutics NASDAQ:SPRO$0.75 +0.01 (+1.92%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.76 +0.01 (+0.77%) As of 04/17/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
